Abstract
The efficacy of cancer therapy is compromised by the fact that there are currently no good ways to predict which patients will benefit from treatment. This long standing goal is closer to becoming a reality as more is learned about the molecules that affect the activities of various therapeutic agents. The fluoropyrimidine antimetabolites drugs have been in clinical use for over 4 decades and the cellular proteins important for their activities have been studied in detail. The most important are the major target enzyme, thymidylate synthase (TS) and the rate limiting enzyme in the degradation pathway, dihydropyrimidine dehydrogenase (DPD), equally important for the analogue capecitabine is thymidine phosphorylase (TP), which is rate limiting for activation of this prodrug. A number of assays are available for these enzymes, including enzyme activity measurements, quantitative PCR for RNA expression and immunological methods for protein expression. With each of these methods, more clinical studies are required to validate their clinical usefulness.
Keywords: 5-fluorouracil, capecitabine, quantitative immunofluorescence, pcr, elisa, thymidine phosphorylase, dihydropyridine dehydrogenase
Current Drug Targets
Title: Potential for Predicting Toxicity and Response of Fluoropyrimidines in Patients
Volume: 5 Issue: 4
Author(s): James F. Eliason and Attila Megyeri
Affiliation:
Keywords: 5-fluorouracil, capecitabine, quantitative immunofluorescence, pcr, elisa, thymidine phosphorylase, dihydropyridine dehydrogenase
Abstract: The efficacy of cancer therapy is compromised by the fact that there are currently no good ways to predict which patients will benefit from treatment. This long standing goal is closer to becoming a reality as more is learned about the molecules that affect the activities of various therapeutic agents. The fluoropyrimidine antimetabolites drugs have been in clinical use for over 4 decades and the cellular proteins important for their activities have been studied in detail. The most important are the major target enzyme, thymidylate synthase (TS) and the rate limiting enzyme in the degradation pathway, dihydropyrimidine dehydrogenase (DPD), equally important for the analogue capecitabine is thymidine phosphorylase (TP), which is rate limiting for activation of this prodrug. A number of assays are available for these enzymes, including enzyme activity measurements, quantitative PCR for RNA expression and immunological methods for protein expression. With each of these methods, more clinical studies are required to validate their clinical usefulness.
Export Options
About this article
Cite this article as:
Eliason F. James and Megyeri Attila, Potential for Predicting Toxicity and Response of Fluoropyrimidines in Patients, Current Drug Targets 2004; 5 (4) . https://dx.doi.org/10.2174/1389450043345461
DOI https://dx.doi.org/10.2174/1389450043345461 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Melatonin, a Potential Therapeutic Agent for Smooth Muscle-Related Pathological Conditions and Aging
Current Medicinal Chemistry Current and Future Scenario of Immunotherapy for the Treatment of Hepatocellular Carcinoma
Current Cancer Therapy Reviews Proteomics in the Search for Biomarkers of Animal Cancer
Current Protein & Peptide Science The Complexity of DEK Signaling in Cancer Progression
Current Cancer Drug Targets Arylurea Derivatives: A Class of Potential Cancer Targeting Agents
Current Topics in Medicinal Chemistry Yin and Yang of Polyphenols in Cancer Prevention: A Short Review
Anti-Cancer Agents in Medicinal Chemistry AFM-Based Single Molecule Techniques: Unraveling the Amyloid Pathogenic Species
Current Pharmaceutical Design Epigenetic Changes Induced by Green Tea Catechins a re Associated with Prostate Cancer
Current Molecular Medicine Novobiocin and Additional Inhibitors of the Hsp90 C-Terminal Nucleotide- binding Pocket
Current Medicinal Chemistry Drugs Made of RNA: Development and Application of Engineered RNAs for Gene Therapy
Mini-Reviews in Medicinal Chemistry A Prospective Study of the Clinical and Demographic Profile of Type 2 Diabetes Mellitus Patients Receiving Antidiabetic Drug Combinations
Current Diabetes Reviews Targeted Nanostructured Lipid Carriers for Delivery of Paclitaxel to Cancer Cells: Preparation, Characterization, and Cell Toxicity
Current Drug Delivery Multiple Functions of Generic Drugs: Future Perspectives of Aureolic Acid Group of Anti-Cancer Antibiotics and Non-Steroidal Anti-Inflammatory Drugs
Mini-Reviews in Medicinal Chemistry New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening Multi-target Drug Discovery via PTML Modeling: Applications to the Design of Virtual Dual Inhibitors of CDK4 and HER2
Current Topics in Medicinal Chemistry Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design Pharmacogenomics of Xenobiotic Metabolizing Enzymes in South American Populations
Current Pharmacogenomics Prostaglandin E Synthase: A Novel Drug Target for Inflammation and Cancer
Current Pharmaceutical Design Mechanisms of Resistance to Photodynamic Therapy
Current Medicinal Chemistry